Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsInterest & Investment IncomeNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Roivant Sciences (ROIV) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Roivant Sciences (ROIV) over the last 6 years, with Q4 2025 value amounting to $341.2 million.

  • Roivant Sciences' Operating Expenses rose 2037.87% to $341.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $936.0 million, marking a year-over-year increase of 1009.75%. This contributed to the annual value of $1.1 billion for FY2025, which is 2925.52% up from last year.
  • Roivant Sciences' Operating Expenses amounted to $341.2 million in Q4 2025, which was up 2037.87% from $307.8 million recorded in Q3 2025.
  • In the past 5 years, Roivant Sciences' Operating Expenses ranged from a high of $698.4 million in Q3 2021 and a low of $162.1 million during Q2 2021
  • Moreover, its 5-year median value for Operating Expenses was $287.1 million (2025), whereas its average is $309.6 million.
  • Per our database at Business Quant, Roivant Sciences' Operating Expenses soared by 34241.63% in 2021 and then tumbled by 5800.51% in 2022.
  • Roivant Sciences' Operating Expenses (Quarter) stood at $270.4 million in 2021, then skyrocketed by 46.15% to $395.1 million in 2022, then crashed by 40.14% to $236.5 million in 2023, then grew by 19.82% to $283.4 million in 2024, then rose by 20.38% to $341.2 million in 2025.
  • Its last three reported values are $341.2 million in Q4 2025, $307.8 million for Q3 2025, and $287.1 million during Q2 2025.